Publications by authors named "Rustem A Gafanov"

Claim this Profile
A
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
Primo N Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Rustem Airatovich Gafanov

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, Sang Joon Shin, Jae Lyun Lee, Rustem Airatovich Gafanov

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, Marek Ziobro, Cristina Suarez, Przemyslaw Langiewicz, Rustem Airatovich Gafanov

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis